



Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Result of AGM

Oxford, UK - 26 January 2026 - Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that all resolutions proposed at the Company's Annual General Meeting, held earlier today, were duly passed. The proxy votes received for the AGM were as shown below:

Resolution	Votes for	%	Votes against	%	Chairman's Discretion	%	Abstentions / Votes withheld
Ordinary Resolutions							
1. To receive the financial statements and the reports of the Directors and the Auditors for the year ended 30 September 2025	1,913,765,673	99.96	13,252	0.00	722,754	0.04	687,222
2. To approve the report of the Remuneration Committee for the year ended 30 September 2025	1,200,415,738	62.71	713,218,083	37.26	722,754	0.04	832,326
3. To elect Peter Presland as a Director of the Company	1,910,939,324	99.82	2,808,322	0.15	722,754	0.04	718,501
4. To re-elect Dr Alexandre Akoulitchiev as a Director of the Company	1,910,863,980	99.81	2,881,251	0.15	722,754	0.04	720,916
5. To re-elect Dr David Holbrook as a Director of the Company	1,199,722,309	62.67	714,042,922	37.30	722,754	0.04	700,916
6. To re-elect Iain Ross as a Director of the Company	1,907,689,355	99.64	6,075,280	0.32	722,754	0.04	701,512
7. To re-elect Paul Stockdale as a Director of the Company	1,910,898,407	99.81	2,866,824	0.15	722,754	0.04	700,916
8. To re-appoint Grant Thornton UK LLP as Auditors of the Company	1,913,079,280	99.93	676,192	0.04	722,754	0.04	710,675
9. To authorise the Directors to set the remuneration of the Auditor	1,911,916,081	99.87	1,827,754	0.10	722,754	0.04	722,312
10. To authorise the Directors to allot shares in the Company	1,910,460,099	99.80	3,113,162	0.16	722,754	0.04	892,886
Special Resolutions							
11. To disapply statutory pre-emption rights in connection with a rights issue or other pre-emptive issue	1,845,833,984	96.42	67,888,556	3.55	722,754	0.04	743,607
12. To disapply statutory pre-emption rights in connection with an acquisition or a specified capital investment	1,846,582,870	96.46	67,136,765	3.51	722,754	0.04	746,512
13. To authorise the Company to make market purchases of its own shares	1,852,677,167	96.77	61,083,956	3.19	722,754	0.04	705,024

The Board notes the proportion of shareholders' votes which were against ordinary resolutions two and five. The Board intends to consult with shareholders to understand their views.

-Ends-

For further details please contact:

Oxford BioDynamics Plc	Tel: +44 (0)1865 518910
Iain Ross Executive Chairman Paul Stockdale, CFO	
Shore Capital - Nominated Adviser and Broker	Tel: +44 (0)20 7408 4090
Stephane Auton / Lucy Bowden	

Stephen / Nathan / Lucy Brown	
OAK Securities - Joint Broker	Tel: +44 (0)20 3973 3678
Matthew Clarke / Tim Dainton / Calvin Man	
Camarco - Financial PR	Tel: +44 (0)20 3757 4980
Marc Cohen / Tilly Butcher / Fergus Young	OBDFinancial@camarco.co.uk

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the [EpiSwitch® PSE](#) (EpiSwitch Prostate Screening test) and [EpiSwitch® CiRT](#) (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or [LinkedIn](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGUNRURNWUAUAR